3M announced the appointment of Bryan C. Hanson as Chief Executive Officer of the independent health care company when it is spun off from 3M. Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.

Hanson comes to 3M from Zimmer Biomet. He has served as President and Chief Executive Officer since 2017, and Chairman since 2021. Hanson is a proven executive with a track record of successfully leading, growing, and transforming global medical device businesses to achieve greater innovation, commercial success, and driving value for customers, patients, and shareholders.

His industry expertise, ability to drive growth, and track record of building a strong culture and teams will make an immediate impact. Prior to joining Zimmer Biomet, Hanson was Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group, where he oversaw and provided strategic direction to an approximately $9 billion business. Prior to Medtronic, he served in a number of executive roles of increasing responsibility at Covidien.

In 2013, he was named Group President of Covidien's Medical Devices business. In 2011, as Surgical Solutions Group President, Hanson transformed two of Covidien's divisions--Energy-based Devices and Surgical Devices--into one global business unit. Hanson serves on the board of directors of Walgreens Boots Alliance Inc. He also serves on the board of the Advanced Medical Technology Association, is a member of its International Board Committee and chairs the China subcommittee.

He is a director emeritus of the Americares board of directors, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis. Carrie Cox Named Chairman of the Board of Directors of the New Health Care Company 3M also announced that Carrie Cox, a health care industry veteran, will serve as the Chairman of the Board of Directors of the independent Health Care company. Cox currently serves as the Chairman of the Board of Organon, and on the Boards of Directors of Cardinal Health, Selecta BioSciences, and Texas Instruments.

She previously served as Chairman and Chief Executive Officer of Humacyte, which she joined in 2010. She also served for 10 years on the board of Celgene (2009-2018) until its sale to Bristol-Myers Squibb. Cox spent her early career at Sandoz Pharmaceuticals (now Novartis) in a variety of commercial roles.

She was later President of Global Prescription Business at Schering-Plough, Senior Vice President of Global Business Management at Pharmacia & Upjohn, as well as Vice President of Women's Health Care at Wyeth-Ayerst. She is a graduate of the Massachusetts College of Pharmacy and Health Sciences. Monish Patolawala Appointed 3M President and Chief Financial Officer Monish Patolawala is appointed 3M President and Chief Financial Officer, effective Sept.

1. In this role, he will add responsibility for executing country prioritization and country governance to his current responsibilities which include leadership of finance, information technology, office for separation management for the upcoming spin off of Health Care, office for project management as the company executes on announced actions, enterprise strategy, and 3M's global service centers.